According to Zhitong Finance App News, Boan Biotech (06955) announced that it is expected that in the six months ending June 30, 2026 (reporting period), the Group will obtain a net loss attributable to the company's equity holders of about RMB 79 million to RMB 89 million, while for the six months ending June 30, 2025, the net profit attributable to the equity holders of the company is approximately RMB 21 million.

The board of directors believes that the Group's profit and loss during the reporting period was mainly due to the increase in R&D expenses brought about by the acceleration of the Group's innovation strategy. Various drug candidates promoted clinical trials and key preclinical research, including BA1106 (anti-CD25 monoclonal antibody), BA1302 (targeted CD228 ADC), BA1203 (PD-1/IL-2 antibody cytokine precursor), BA2201 (TL1A/23IL-19 double antibody), and BA1304 (EGFR/B7-H3 dual antibody ADC). As a result, clinical trial expenses and R&D expenses for these projects increased significantly during the reporting period.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.